Targeting the vascular endothelial growth factor in hematologic malignancies

被引:17
作者
Paesler, Julian [1 ]
Gehrke, Iris [1 ]
Poll-Wolbeck, Simon Jonas [1 ]
Kreuzer, Karl-Anton [1 ]
机构
[1] Univ Cologne, Dept Internal Med 1 1, D-50937 Cologne, Germany
关键词
vascular endothelial growth factor; vascular endothelial growth factor receptor; acute leukemias; chronic leukemias; multiple myeloma; non-Hodgkin lymphoma; Hodgkin's lymphoma; ACUTE MYELOID-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; TYROSINE KINASE INHIBITOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; FACTOR VEGF EXPRESSION; REED-STERNBERG CELLS; NON-HODGKIN-LYMPHOMA; BONE-MARROW; MULTIPLE-MYELOMA; PROGNOSTIC-SIGNIFICANCE;
D O I
10.1111/ejh.12009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There exists increasing evidence that apart from solid tumors, angiogenic growth factors also play important roles in the development and/or maintenance of hematolymphoid malignancies. Thus, in these cancers, angiogenesis and bone marrow microvessel density often correlate with prognosis and disease burden. Several reports speculated on the role of angiogenesis and the resulting possible therapeutic options in hematologic malignancies. The most prominent angiogenic factor, vascular endothelial growth factor (VEGF), is expressed in a number of established leukemic cell lines as well as in freshly isolated human leukemias and lymphomas, and several human leukemias express VEGF receptor 1 and/or VEGF receptor 2. VEGF/VEGF-receptor interactions are also involved in proliferation, migration, and survival of leukemic cells by autocrine and paracrine mechanisms. As a consequence, a possible drugable effect by inhibiting VEGF signaling in different hematologic malignancies has been discussed. This review focuses on angiogenesis-independent effects of VEGF on survival and proliferation of leukemic or lymphoma cells and on possible therapeutic approaches using anti-VEGF/VEGF-receptor therapies to inhibit proliferation or induce apoptosis of malignant cells in hematologic diseases.
引用
收藏
页码:373 / 384
页数:12
相关论文
共 125 条
  • [51] t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt
    Imai, Norikazu
    Shikami, Masato
    Miwa, Hiroshi
    Suganuma, Kazuto
    Hiramatsu, Akihito
    Watarai, Masaya
    Satoh, Atsushi
    Itoh, Masato
    Imamura, Akira
    Mihara, Hidetsugu
    Nitta, Masakazu
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (05) : 673 - 682
  • [52] Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor
    Imai, Norikazu
    Miwa, Hiroshi
    Shikami, Masato
    Suganuma, Kazuto
    Gotoh, Mayuko
    Hiramatsu, Akihito
    Wakabayashi, Motohiro
    Watarai, Masaya
    Hanamura, Ichiro
    Imamura, Akira
    Mihara, Hidetsugu
    Shitara, Kenya
    Shibuya, Masabumi
    Nitta, Masakazu
    [J]. LEUKEMIA RESEARCH, 2009, 33 (12) : 1650 - 1657
  • [53] Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas
    Jorgensen, Judit M.
    Sorensen, Flemming B.
    Bendix, Knud
    Nielsen, Johan L.
    Funder, Anette
    Karkkainen, Marika J.
    Tainola, Tapio
    Sorensen, Annette B.
    Pedersen, Finn S.
    D'Amore, Francesco
    [J]. LEUKEMIA & LYMPHOMA, 2009, 50 (10) : 1647 - 1660
  • [54] Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias:: Therapy with sequential 1-β-D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab
    Karp, JE
    Gojo, I
    Pili, R
    Gocke, CD
    Greer, J
    Guo, CF
    Qian, D
    Morris, L
    Tidwell, M
    Chen, H
    Zwiebel, J
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (11) : 3577 - 3585
  • [55] B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules
    Kay, NE
    Bone, ND
    Tschumper, RC
    Howell, KH
    Geyer, SM
    Dewald, GW
    Hanson, CA
    Jelinek, DF
    [J]. LEUKEMIA, 2002, 16 (05) : 911 - 919
  • [56] Koomagi R, 2001, CLIN CANCER RES, V7, P3381
  • [57] A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma-NCIC CTG IND.145
    Kovacs, Michael J.
    Reece, Donna E.
    Marcellus, Deborah
    Meyer, Ralph M.
    Mathews, Sarah
    Dong, Rui-Ping
    Eisenhauer, Elizabeth
    [J]. INVESTIGATIONAL NEW DRUGS, 2006, 24 (06) : 529 - 535
  • [58] Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease
    Krauth, MT
    Simonitsch, I
    Aichberger, KJ
    Mayerhofer, M
    Sperr, WR
    Sillaber, C
    Schneeweiss, B
    Mann, G
    Gadner, H
    Valent, P
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 121 (04) : 473 - 481
  • [59] Expression of VEGF and its receptors by myeloma cells
    Kumar, S
    Witzig, TE
    Timm, M
    Haug, J
    Wellik, L
    Fonseca, R
    Greipp, PR
    Rajkumar, SV
    [J]. LEUKEMIA, 2003, 17 (10) : 2025 - 2031
  • [60] Le Gouill Steven, 2004, Blood, V104, P2886